Pharmacokinetic study of puerarin in rat serum by liquid chromatography tandem mass spectrometry

被引:38
作者
Prasain, Jeevan K.
Peng, Ning
Acosta, Edward
Moore, Ray
Arabshahi, Alireza
Meezan, Elias
Barnes, Stephen
Wyss, J. Michael
机构
[1] Univ Alabama Birmingham, Dept Pharmacol & Toxicol, Birmingham, AL 35294 USA
[2] Univ Alabama Birmingham, Dept Cell Biol, Birmingham, AL 35294 USA
[3] Univ Alabama Birmingham, Comprehens Canc Ctr Mass Spectrometry Shared Faci, Birmingham, AL 35294 USA
[4] Univ Alabama Birmingham, Purdue UAB Bot Ctr Agerelated Dis, Birmingham, AL 35294 USA
关键词
puerarin; pharmacokinetics; serum; rats; LC-MS/MS;
D O I
10.1002/bmc.772
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
A highly sensitive and specific atmospheric pressure chemical ionization liquid chromatography-tandem mass spectrometry method was developed for serum pharmacokinetic studies of puerarin in rats. Chromatography was carried out on a reversed-phase Phenomenex Synergi 4 mu m Fusion-RP80 column (150 x 2.0 mm W.) using a mobile phase consisting of acetonitrile-water (10:90, v/v) in 10 mM NH4OAc with a flow rate of 0.2 mL/min. Puerarin was analyzed in the multiple reaction monitoring mode with a precursor/product ion transition of m/z 415/267. The method was demonstrated to be specific and sensitive, and a linear response was observed over a range of 2-5000 ng/mL in rat serum. The validated method was successfully applied to the characterization of the pharmacokinetics of puerarin in rat serum after oral administration to spontaneously hypertensive rats. The blood concentration-time profile of puerarin showed a rapid initial increase, reaching a maximum and then declining within 1 h. Puerarin could not be detected after 24 h. The main pharmacokinetic parameters for puerarin after oral administration were as follows: C-max (3.54 +/- 2.03 mg/L), T-max (0.68 +/- 0.37 h), AUC(0-1) (7.29 +/- 3.79 mg h/L), AUC(0-infinity) (9.17 +/- 4.87 mg h/L), T-1/2 (1.7 +/- 0.6 h), CL/F (7.24 +/- 4.27 L/h/kg) and V/F (17.88 +/- 13.55 L/h/kg). Copyright (c) 2007 John Wiley & Sons, Ltd.
引用
收藏
页码:410 / 414
页数:5
相关论文
共 11 条
[1]   Antihyperglycemic effect of puerarin in streptozotocin-induced diabetic rats [J].
Hsu, FL ;
Liu, IM ;
Kuo, DH ;
Chen, WC ;
Su, HC ;
Cheng, JT .
JOURNAL OF NATURAL PRODUCTS, 2003, 66 (06) :788-792
[2]   Plasma and urinary kinetics of the isoflavones daidzein and genistein after a single soy meal in humans [J].
King, RA ;
Bursill, DB .
AMERICAN JOURNAL OF CLINICAL NUTRITION, 1998, 67 (05) :867-872
[3]   Pharmacokinetic, tissue distribution, and excretion of puerarin and puerarin-phospholipid complex in rats [J].
Li, Y ;
Pan, WS ;
Chen, SL ;
Xu, HX ;
Yang, DJ ;
Chan, ASC .
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2006, 32 (04) :413-422
[4]   Determination of puerarin in human plasma by high performance liquid chromatography [J].
Ma, ZZ ;
Wu, QL ;
Lee, DYW ;
Tracy, M ;
Lukas, SE .
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2005, 823 (02) :108-114
[5]   Contrasting effects of puerarin and daidzin on glucose homeostasis in mice [J].
Meezan, E ;
Meezan, EM ;
Jones, K ;
Moore, R ;
Barnes, S ;
Prasain, JK .
JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 2005, 53 (22) :8760-8767
[6]   Identification of puerarin and its metabolites in rats by liquid chromatography-tandem mass spectrometry [J].
Prasain, JK ;
Jones, K ;
Brissie, N ;
Moore, R ;
Wyss, JM ;
Barnes, S .
JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 2004, 52 (12) :3708-3712
[7]   Quantitative determination of puerarin in dog plasma by HPLC and study on the relative bioavailability of sustained release tablets [J].
Ren, Fuzheng ;
Jing, Qiufang ;
Shen, Yongjia ;
Ma, Hongmei ;
Cui, Jingbin .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2006, 41 (02) :549-553
[8]   Matrix effects during analysis of plasma samples by electrospray and atmospheric pressure chemical ionization mass spectrometry: practical approaches to their elimination [J].
Schuhmacher, J ;
Zimmer, D ;
Tesche, F ;
Pickard, V .
RAPID COMMUNICATIONS IN MASS SPECTROMETRY, 2003, 17 (17) :1950-1957
[9]   Bioavailability of pure isoflavones in healthy humans and analysis of commercial soy isoflavone supplements [J].
Setchell, KDR ;
Brown, NM ;
Desai, P ;
Zimmer-Nechemias, L ;
Wolfe, BE ;
Brashear, WT ;
Kirschner, AS ;
Cassidy, A ;
Heubi, JE .
JOURNAL OF NUTRITION, 2001, 131 :1362S-1375S
[10]  
Xu XH, 2002, ACTA PHARMACOL SIN, V23, P587